Management of disease-related anemia in patients with multilple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations

Hematology Journal

Volumn 3, Issue 3, 2002, Pages 121-130

  Ludwig, Heinz ^a   Rai, Kanti ^a   Blade, Joan ^a   Dammacco, Franco ^a   Degos, Laurent ^a   Itri, Loretta ^a   Kyle, Robert ^a   Liso, Vicenzo ^a   Littlewood, Timothy J ^a   Mandelli, Franco ^a   Meloni, Giovanna ^a   Molica, Sterfano ^a   Osterborg, Anders ^a   Pangalis, Gerassimos A ^a   San Miguel, Jesus ^a   Schmitt, Barbara ^a   Voliotis, Dimitrios ^a  

^a Det of Medicine/Medical Oncology   (Austria)

Author keywords

Anemia; Chronic lymphocytic leukemia; Epoetin; Multiple myeloma; Recombinant human erythropoietin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERYTHROPOIETIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; HUMAN; INFECTION; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; DISEASE MANAGEMENT; PRACTICE GUIDELINE; REVIEW;

ANEMIA; DISEASE MANAGEMENT; EPOETIN ALFA; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MULTIPLE MYELOMA; PRACTICE GUIDELINES;

EID: 0036049054     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200160     Document Type: Article

References (51)

1. Erythropoiesis and erythropoietin in multiple myeloma
2. Anemia in cancer patients
3. Progress in understanding the pathogenesis of the anemia of chronic disease
4. Anemia of chronic disease
5. Decreased erythropoietin response in patients with the anemia of cancer
6. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production
7. Multiple myeloma: Review of 869 cases
8. Chronic lymphocytic leukemia and myeloma: Update on the biology and management
9. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
10. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
11. Factors influencing quality of life in cancer patients: Anemia and fatigue
12. A new staging system for multiple myeloma based on the number of S-phase plasma cells
13. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study
14. Multiple myeloma
15. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
16. Treatment of multiple myeloma
17. Recombinant human erythropoietin and the anemia of multiple myeloma
18. Special report: Transfusion risks
19. Effects of transfusion on immune function. Cancer recurrence and infection
20. Transfusion-induced immunologic unresponsiveness
21. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
22. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
23. Effects of epoetin alfa on hematologic parameters and qualify of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
24. Erythropoietin for anaemia in cancer patients
25. Clinical applications of visual analogue scales: A critical review
26. Assessment of the quality of life of patients with advanced cancer
27. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
28. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
29. Erythropoietin treatment of anemia associated with multiple myeloma
30. Increase of bone marrow cellularity during erythropoietin treatment in myeloma
31. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer
32. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
33. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
34. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study
35. Prediction of response to erythropoietin treatment in chronic anemia of cancer
36. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial
37. Does baseline endogenous erythropoietin level impact hemoglobin (Hb) response to r-HuEPO in cancer patients?
38. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
39. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
40. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)
41. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin
42. Correction of disease-related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: Maintenance is necessary to sustain response
43. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma
44. Epoetin alfa: Into the new millennium
45. Guidelines for the use of recombinant human erythropoietin
46. Hairy cell leukemia: A review
47. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL)
48. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
49. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases
50. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia
51. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders